Advertisement

Rezeptorentest (Wirkung von Tropicamide)

  • Josef Grünberger
Chapter
  • 50 Downloads

Abstract

Multiple sclerosis (MS; also known as encephalomyelitis), is characterized by the onset in early and adult life of progressive diffuse neurologic disturbances with an irregular fluctuating period of exacerbation and apparent improvement or quiescence. Irregular gray patches of degeneration occur in the brain and spinal cord with a predilection for the white matter, varying in size from a few millimeters to several centimeters. Signs of multiple involvement of the central nervous system (CNS) may include slurred speech, intention tremor, nystagmus, retrobulbar neuritis, incontinence, spastic paralysis, pallor of the temporal halves of the optic disks, increased deep tendon reflexes, and bilateral extensor plantar responses.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. [1]
    Grünberger J, Linzmayer L, Grünberger M, Saletu B (1992) Pupillometry in clinical psychophysiological diagnostics: methodology and proposals for application in psychiatry. Isr J Psychiatry Relat Sci 28 (2): 100–113Google Scholar
  2. [2]
    Grünberger J, Linzmayer L, Grünberger M, Saletu B (1994) Eine neue Methode zur Messung der zentralen Aktivierung: Fourieranalyse der Pupillenoszillationen bei depressiven Patienten. Wien Klin Wochenschr 106 (6): 164–170Google Scholar
  3. [3]
    Schandry R (1981) Psychophysiologie. Körperliche Indikatoren menschlichen Verhaltens. Urban and Schwarzenberg, MünchenGoogle Scholar
  4. [4]
    Scinto LFM, Dafrher KR, Dressier D, Ransil BI, Rentz D, Weintraub S, Mesulam M, Potter H (1994) A potential noninvasive neurobiological test for Alzheimer’s disease. Science 266 (5187): 1051–1054PubMedGoogle Scholar
  5. [5]
    Scinto LFM, Daffher KR, Dressier D, Rentz D, Ransil BI, Potter H (1995) Hypersensitive pupillary dilatation to a cholinergic antagonist as a diagnostic test for Alzheimer’s disease. In: Iqbal K, Mortimer JA, Winblad D, Wisniewski HH (eds) Research advances in Alzheimer’s disease and related disorders. Wiley, New York, pp 161–172Google Scholar

References

  1. [1]
    American Psychiatric Association (1994) Diagnostic and Statistical Manual of Mental Disorders, 4th edn. American Psychiatric Association, Washington, DCGoogle Scholar
  2. [2]
    World Health Organization (1992) The ICD-10 Classification of Mental and Behavioural Disorders. World Health Organization, GenevaGoogle Scholar
  3. [3]
    Grünberger J, Linzmayer L, Feuerlein W (1988) Psychische Veränderungen beim Alkoholmißbrauch. Internist 29: 307–312PubMedGoogle Scholar
  4. [4]
    Löwenstein O, Feinberg R, Löwenfeld E (1963) Pupillary movements during acute and chronic fatigue. A new test for the objective evaluation of tiredness. Investigations in Ophthalmology 2: 138–157Google Scholar
  5. [5]
    Griinberger J, Linzmayer L, Saletu B (1994) Eine neue Methode zur Messung der zentralen Aktivierung: Fourieranalyse der Pupillenoszillationen bei depressiven Patienten. Wien Klin Wschr 106: 164–170Google Scholar
  6. [6]
    Schandry R (1981) Psychophysiologie. Körperliche Indikatoren menschlichen Verhaltens. Urban & Schwarzenberg, MünchenGoogle Scholar
  7. [7]
    Wilhelm H (1991) Pupillenreaktionen und Pupillenstörungen. Kohlhammer, KölnGoogle Scholar
  8. [8]
    Saletu-Zyhlarz G, Saletu B, Anderer P, Brandstätter N, Frey R, Gruber G, Klösch G, Mandl M, Griinberger J, Linzmayer L (1997) Nonorganic insomnia in gereralized anxiety disorder: I. Controlled studies on sleep, awakening and daytime vigilance utilizing polysomnography and EEG mapping. Neuropsychobiol 36: 117–129Google Scholar
  9. [9]
    Grünberger J, Linzmayer L, Reitner A, Walter H, Rainer M, Maschig A, Pezawas L, Saletu-Zyhlarz G, Stöhr H, Griinberger M (1998) Receptor test (pupillary dilatation after application of 0.01% tropicamide solution) and determination of central nervous activation (Fourier analysis of pupillary oscillations) in patients with Alzheimer’s disease. NeuropsychobiolGoogle Scholar
  10. [10]
    Schubö W, Uehlinger HM (1986) SPSS. Fischer, StuttgartGoogle Scholar
  11. [11]
    Korczyn AD (1987) The pupil and vigilance. Functional Neurology 2: 539–544PubMedGoogle Scholar
  12. [12]
    Grünberger J, Linzmayer L, Wytek R, Griinberger M (1996) Die kognitive Pupillenoszillationshypothese bei Patienten mit neurotischen Störungen bzw. organischem Psychosyndrom und Validität eines neuen psychophysiologischen Verfahrens. Wien Klin Wschr 108: 69–74PubMedGoogle Scholar
  13. [13]
    Scinto LFM, Daffher KR, Dressier D, Ransil BI, Rentz D, Weintraub S, Mesulam M, Potter, H (1994) A potential noninvasive neurobiological test for Alzheimer’s disease. Science 266: 1051–1054PubMedGoogle Scholar
  14. [14]
    Gustafson B, Wigstrom H (1988) Physiological mechanisms underlying long-term potentiation. Trends in Neurosciences 11: 152–162Google Scholar
  15. [15]
    Maragos WF, Greenamyre JT, Penney JB, Young AB (1987) Glutamate dysfunction in Alzheimer’s disease: an hypothesis. Trends in Neurosciences 10: 65–68Google Scholar
  16. [16]
    American Psychiatric Association (1987) Diagnostic and Statistical Manual of Mental Disorders, 3rd edn. American Psychiatric Association, Washington, DCGoogle Scholar
  17. [17]
    Lesch OM, Walter H, Rommelspacher H (1996) Alcohol abuse and alcohol dependence. In: Baillière’s Clinical Psychiatry: Rommelspacher H, Schuckit, MA (eds) Drugs of Abuse. Baillière Tindall, New York, pp 421–444Google Scholar
  18. [18]
    Saletu B, Saletu-Zyhlarz G, Anderer P, Brandstätter N, Frey R, Gruber G, Kösch G, Mand, M, Grünberger J, Linzmayer L (1997) Nonorganic insomnia in generalized anxiety disorder. 2. Comparative studies on sleep, awakening, daytime vigilance and anxiety under lorazepam plus diphenhydramine (Somnium®) versus lorazepam alone, utilizing clinical, polysomnographic and EEG mapping methods. Neuropsychobiol 36: 130–152Google Scholar
  19. [19]
    Grünberger J, Linzmayer L, Grünberger, M, Saletu B (1992) Pupillometry in clinical psychophysiological diagnostics: methodology and proposals for application in psychiatry. Israel Journal of Psychiatry and Related Sciences 29: 100–113PubMedGoogle Scholar
  20. [20]
    CooleyJU, TukeyJK (1965) An algorithm for the machine calculation of complex Fourier series. Mathematic Computing 19: 297–301Google Scholar
  21. [21]
    Schäfer N, Bertuch M (1986) Butterfly-algorithmus. Magazin Computertechnik 8: 44–50Google Scholar

References

  1. [1]
    Scinto LFM, Daffner KR, Dressier D, Rentz D, Ransil BI, Potter H (1995) Hypersensitive pupillary dilatation to a cholinergic antagonist as a diagnostic test for Alzheimer’s disease. In: Igbal K, Mortimer JA, Wiesniewski HH: Research Advances in Alzheimer’s disease and related disorders. Wiley, New York, pp 161–172Google Scholar
  2. [2]
    Löwenstein O, Feinberg R, Löwenfeld E (1963) Pupillary movements during acute and chronic fatigue. A new test for the objective evaluation of tiredness. Invest Ophthalmol 2: 138–157Google Scholar
  3. [3]
    Grünberger J, Linzmayer L, Grünberger M, Saletu B (1994) Eine neue Methode zur Messung der zentralen Aktivierung: Fourier Analyse der Pupillenoszillationen bei depressiven Patienten.Wien Klin Wochenschr 106: 164–170Google Scholar
  4. [4]
    Schandry R (1981) Psychophysiologie. Körperliche Indikatoren menschlichen Verhaltens. Urban & Schwarzenberg, MünchenGoogle Scholar
  5. [5]
    Wilhelm H (1991) Pupillenoszillationen und Pupillenstörungen. Kohlhammer, KölnGoogle Scholar
  6. [6]
    Saletu-Zyhlarz G, Saletu B, Anderer P, Brandstätter N, Frey R, Gruber G, Klösch G, Mandl M, Grünberger J, Linzmayer L (1997) Nonorganic insomnia in generalized anxiety disorder. I. Controlled studies on sleep, awakening and daytime vigilance utilizing polysomnography and EEG mapping. Neuropsychobiology 36: 117–129Google Scholar
  7. [7]
    Saletu B, Saletu-Zyhlarz G, Anderer P, Brandstätter N, Frey R, Gruber G, Klösch G, Mandl M, Grünberger J, Linzmayer L (1997) Nonorganic insomnia in generalized anxiety disorder: II. Comparative studies on sleep, awakening, daytime vigilance and anxiety under lorazepam plus diphenhydramine (Somnium R) versus lorazepam alone, utilizing clinical, polysomnographic and EEG mapping methods. Neuropsychobiology 36: 130–152PubMedGoogle Scholar
  8. [8]
    Folstein MF, Fostein SE, Mc Hugh RP (1990) Deutsche Bearbeitung: Kessler J, Markowitsch HJ, Denzler P: Mini-Mental-Status-Test (MMST). Beltz, WeinheimGoogle Scholar
  9. [9]
    Grünberger J, Linzmayer L, Grünberger M, Saletu B (1992) Pupillometry in clinical psychophysiological diagnostics: Methodology and proposals for application in psychiatry. Isr J Psychiatry Relat Sci 29: 100–113PubMedGoogle Scholar
  10. [10]
    Grünberger J, Linzmayer L, Wytek R, Grünberger M (1996) Die kognitive Pupillenoszillations-hypothese bei Patienten mit neurotischen Persönlichkeitsstörungen und organischem Psychosyndrom. Wien Klin Wochenschr 108: 69–74PubMedGoogle Scholar
  11. [11]
    Sachs L (1972) Statistische Auswertungsmethoden. Springer, BerlinGoogle Scholar
  12. [12]
    Fährmeir L, Häußler W, Tutz G (1984) Diskriminanzanalyse in multivariate statistische Verfahren.Berlin, Walter de GruyterGoogle Scholar
  13. [13]
    Francis PT, Sims NR, Procter AW, Bowen DM (1993) Corticalpyramidal neurone loss may cause glutaminergic hypoactivity and cognitive impairment Alzheimer’s disease: Investigative and therapeutic perspectives. J Neurochem 60: 1589–1604PubMedGoogle Scholar
  14. [14]
    Scinto LFM, Daffner KR, Dressier D, Ransil BI, Rentz D, Weintraub S. Mesulam M, Potter H(1994) A potential noninvasive neurobiological test for Alzheimer’s disease. Science 266:1051–1054PubMedGoogle Scholar
  15. [15]
    Grünberger J, Linzmayer L, Majda EM, Reitner A, Walter H (1996) Pupillary dilatation test and Fourier analysis of pupillary oscillations on patients with multiple sclerosis. Eur Arch Psychiatry Clin Neurosci 246: 209–212PubMedGoogle Scholar
  16. [16]
    Sastry BV (1985) Cholinergic systems and multiple cholinergic receptors in ocular tissues. J Ocul Pharmacol 1: 201–226PubMedGoogle Scholar
  17. [17]
    Colasanti BK (1987) Autonomic drug effect after chronic lowering of ocular cholinergic input.I. Pupillary responses. J Ocul Pharmacol 3: 23–29PubMedGoogle Scholar
  18. [18]
    Yoss RE, Moyer NJ, Hollenhorst RW(1980) Pupil size and spontaneous pupillary waves associated with alertness, drowsiness and sleep. Neurology 10: 545–554Google Scholar
  19. [19]
    Korczyn AD (1987) The pupil and vigilance. Funct Neurol 2: 539–544Google Scholar

References

  1. [1]
    Rall SC, Mahley RW (1992) The role of apolipoprotein E genetic variants in lipoprotein disorders.J Intern Med 23 1: 653–659Google Scholar
  2. [2]
    Saunders AM, Schmader K, Breitner JC et al (1993) Apolipoprotein E 4 allele distributions in late-onset Alzheimer’s disease and in other amyloid-forming diseases. The Lancet 342: 710–711Google Scholar
  3. [3]
    Houlden H, Crook R, Backhovens H et al (1998) ApoE genotype is a risk factor in nonpresenilin early-onset Alzheimer’s disease families. Am J Med Genet 81: 117–121PubMedGoogle Scholar
  4. [4]
    Talbot C, Lendon C, Craddock N (1994) Protection against Alzheimer’s disease with apoE 2. The Lancet: 343Google Scholar
  5. [5]
    Benjamin R, Leake A, McArthur FK et al (1994) Protective effect of apoE 2 in Alzheimer’s disease. The Lancet: 473Google Scholar
  6. [6]
    Poirier J, Delisle MC, Quirion R et al (1995) Apolipoprotein E4 allele as predictor of cholinergic deficits and treatment outcome in Alzheimer disease. Proc Ntl Acad Sci USA 92: 12260–12264Google Scholar
  7. [7]
    Grünberger J, Linzmayer L, Wittek R, Saletu B (1987) Factor analytic study and determination of rehabilitation of static and dynamic pupillometry in normal persons and psychopathologic groups.Wien Med Wschr 137: 135–139PubMedGoogle Scholar
  8. [8]
    Grünberger J, Linzmayer L, Grünberger M, Saletu B (1992) Pupillometry in clinical psychophysiological diagnostics: methodology and proposals for application in psychiatry. Isr J Psychiatry Relat Sci 29: 100–113PubMedGoogle Scholar
  9. [9]
    Grünberger J, Linzmayer L, Majda EM, Reitner A, Walter H (1996) Pupillary dilatation test and Fourier analysis of pupillary oscillations in patients with multiple sclerosis. Eur Arch Psychiatry Clin Neurosci 246: 209–212PubMedGoogle Scholar
  10. [10]
    Sastry BV (1985) Cholinergic systems and multiple cholinergic receptors in ocular tissues. J Ocul Pharmacol 1:201–226PubMedGoogle Scholar
  11. [11]
    Colasanti BK (1987) Autonomic drug effects after chronic lowering of ocular cholinergic input.I Pupillary responses. J Ocul Pharmacol 3: 23–29PubMedGoogle Scholar
  12. [12]
    Scinto LF, Daffher KR, Dressier D et al (1994) A potential noninvasive neurobiological test for Alzheimer’s disease. Science 266: 1051PubMedGoogle Scholar
  13. [13]
    Loupe DN, Newman NJ, Green RC et al (1996) Pupillary response to tropicamide in patients with Alzheimer disease. Ophthalmology 103: 495–503PubMedGoogle Scholar
  14. [14]
    Treloar AJ, Assin M, Macdonald AJ (1996) Pupillary response to tropicamide as a marker for Alzheimer’s disease. Br J Clin Pharmacol 41: 256–257PubMedGoogle Scholar
  15. [15]
    Fitz Simon JS, Waring SC, Kokmen E, McLaren JW, Brubaker RF (1997) Response of the pupil to tropicamide is not a reliable test for Alzheimer disease. Arch Neurol 54: 155–159Google Scholar
  16. [16]
    Growdon JH, Graefe K, Tennis M, Hayden D, Schoenfeld D, Wray SH (1997) Pupil dilation to tropicamide is not specific for Alzheimer disease. Arch Neurol 54: 841–844PubMedGoogle Scholar
  17. [17]
    Reitner A, Baumgartner I, Thuile C et al (1997) The mydriatic effect of tropicamide and its diagnostic use in Alzheimer’s disease. Vision Re 37: 165–168Google Scholar
  18. [18]
    Graff-Radford NR, Lin SC, Brazis PW et al (1997) Tropicamide eyedrops cannot be used for reliable diagnosis of Alzheimer’s disease. Mayo Clin Proc 72: 495–504PubMedGoogle Scholar
  19. [19]
    Arai H, Terajima M, Nakagawa T, Higuchi S, Mochizuke H (1996) Pupil dilatation assay by tropicamide is modulated by apolipoprotein E 4 allele dosage in Alzheimer’s disease. Neuro Report 7: 918–920Google Scholar
  20. [20]
    Higuchi S, Matsushita S, Hasegawa Y, Muramatsu T, Arai H, Hayashida M (1997) Apolipoprotein E epsilon 4 allele and pupillary response to tropicamide. Am J Psychiatry 154: 694–696PubMedGoogle Scholar
  21. [21]
    Sacks B, Smith S (1989) People with Down’s syndrome can be distinguished on the basis of cholinergic dysfunction. J Neurol Neurosurg Psychiatry 52: 1294–1295PubMedPubMedCentralGoogle Scholar
  22. [22]
    Dillon JR, Tyhurst CW, Yolton RL (1997) The mydriatic effect of tropicamide on light and dark irides. J Am Optom Assoc 48: 653–658Google Scholar
  23. [23]
    Ignatius MJ, Gebicke-Härter PJ, Skene JH, Weisgraber KH, Mahley RW, Shooter EM (1986) Expression of apolipoprotein E during nerve degeneration and regeneration. Proc Natl Acad Sci USA 83: 125–129Google Scholar
  24. [24]
    Horsburgh K, Nicoll JA (1996) Selective alterations in the cellular distribution of apolipoprotein E immunoreactivity following transient cerebral ischaemia in the rat. Neuropathol Appl Neuro-biol 22: 342–349Google Scholar
  25. [25]
    Laskowitz DT, Horsburgh K, Roses AD (1998) Apolipoprotein E and the CNS response to injury.J Cereb Blood Flow Metab 18: 465–467PubMedGoogle Scholar
  26. [26]
    DeMattos SB, Curtiss LK, Williams DL (1998) A minimally lipidated form of cell-derived apolipoprotein E exhibits isoform-specific stimulation of neurite outgrowth in the absence of exogenous lipids or lipoproteins. J Biol Chem 273: 4206–4212PubMedGoogle Scholar
  27. [27]
    Mahley RW, Buttini M, Raber J, Pitas RE, Mucke L (1998) Apolipoprotein E: Insights into the Pathogenesis of Alzheimer’s DiseaseGoogle Scholar
  28. [28]
    Raber J, Wong DT, Buttini M, Orth M, Bellosta S, Pitas RE, Mahley RW, Mucke L (1998) Differential effects of human apolipoprotein isoforms on spatial learning/memory and exploratory behavior revealed in apoE knockout miceGoogle Scholar
  29. [29]
    Sheng H, Laskowitz DT, Bennett ER et al (1998) Apolipoprotein E isoform-specific differences in outcome from focal ischemia in transgenic mice. J Cereb Blood Flow Metab 18: 361–366PubMedGoogle Scholar
  30. [30]
    Arendt T, Schindler C, Brückner MK et al (1997) Plastic neuronal remodeling is impaired in patients with Alzheimer’s disease carrying apolipoprotein epsilon 4 allele. J Neurosci 17: 516–529PubMedPubMedCentralGoogle Scholar
  31. [31]
    Muramatsu T, Kato M, Matsui T et al (1997) Apolipoprotein E -4 allele distribution in Wernicke-Korsakoff syndrome with or without global intellectual deficits. J Neural Transm 104: 913–920PubMedGoogle Scholar
  32. [32]
    Corder EH, Robertson K, Lannfelt L et al (1998) HIV-Infected subjects with the E4 allele for APOE have excess dementia and peripheral neuropathy. Nature Medicine 4: 1182–1184PubMedGoogle Scholar
  33. [33]
    Burlinson S, Burns A, Mann DM, Pickering-Brown SM, Owen F (1998) Effect of apolipoprotein E status on clinical features of dementia. Int J Geriatr Psychiatry 13: 177–185PubMedGoogle Scholar
  34. [34]
    Teasdale GM, Nicoll JA, Murray G, Fiddes M (1997) Association of apolipoprotein E polymorphism with outcome after head injury. The Lancet 350: 1069–1071Google Scholar
  35. [35]
    Hirose N, Homma S, Arai Y et al (1997) (Tokyo Centenarian Study, 4. Apolipoprotein E pheno-type in Japanese centenarians living in the Tokyo Metropolitan areai). Nippon, Ronen, Igakkai, Zasshi 34: 262–272Google Scholar
  36. [36]
    Yasuda M, Mori E, Kitagaki H et al (1998) Apolipoprotein E epsilon 4 allele and whole brain atrophy in lateonset Alzheimer’s disease. Am J Psychiatry 155: 799–804Google Scholar

Literatur

  1. [1]
    Francis PT, Sims NR, Procter AW, Bowen DM (1993) Cortical pyramidal neurone loss may cause glutaminergic hypoactivity and cognitive impairment in Alzheimer’s disease: Investigative and therapeutic perspectives. J Neurochem 60: 1589–1604PubMedGoogle Scholar
  2. [2]
    Grünberger J, Linzmayer L, Wytek R, Grünberger M (1992) Pupillometry in clinical psychophysiological diagnostics: Methodology and proposals for application in psychiatry. Isr J Psychiatry Relat Sci 29: 100–113PubMedGoogle Scholar
  3. [3]
    Grünberger J, Linzmayer L, Grünberger M, Saletu B (1994) Eine neue Methode zur Messung der zentralen Aktivierung: Fourier Analyse der Pupillenoszillationen bei depressiven Patienten. Wien Klin Wochenschr 106: 164–170Google Scholar
  4. [4]
    Grünberger J, Linzmayer L, Wytek R, Grünberger M (1996) Die kognitive Pupillenoszillations-hypothese bei Patienten mit neurotischen Persönlichkeitsstörungen und organischem Psychosyndrom. Wien Klin Wochenschr 108: 69–74PubMedGoogle Scholar
  5. [5]
    Grünberger J, Linzmayer L, Majda EM, Reitner A, Walter H (1996) Pupillary dilatation test and Fourier analysis of pupillary oscillations on patients with multiple sclerosis. Eur Arch Psychiatry Clin Neurosci 246: 209–212PubMedGoogle Scholar
  6. [6]
    Grünberger R, Linzmayer L, Walter H, Stöhr H, Saletu-Zyhlarz GM, Grünberger M, Lesch O (1998) Psychophysiological diagnostics in alcohol dependency: Fourier analysis of pupillary oscillations and the receptor test for determinination of cholinergic deficiency. Alcohol & Alcoholism 33/5: 541–548Google Scholar
  7. [7]
    Grünberger J, Linzmayer L, Walter H, Rainer M, Masching A, Pezawas L, Saletu-Zyhlarz G, Stöhr H, Grünberger M (1998) Receptor test (pupillary dilatation after application of 0.01% tropicamide solution) and determination of central nervous activation (Fourier analysis of pupillary oscillations) in patients with Alzheimer’s disease. Neuropsychobiology 40/1: 40–46Google Scholar
  8. [8]
    Levin ED, Simon BB (1998) Nicotinic acetylcholine involvement in cognitive function in animals: Psychopharmacology 138/3–4: 217–230PubMedGoogle Scholar
  9. [9]
    Löwenstein O, Feinberg R, Löwenfeld E (1963) Pupillary movements during acute and chronic fatigue. A new test for the objective evaluation of tiredness. Invest Ophthalmol 2: 138–157Google Scholar
  10. [10]
    Sachs L (1972) Statistische Auswertungsmethoden. Springer, BerlinGoogle Scholar
  11. [11]
    Saletu B, Saletu-Zyhlarz G, Anderer P, Brandstätter N, Frey R, Gruber G, Klösch G, Mandl M, Grünberger J, Linzmayer L (1997) Nonorganic insomnia in generalized anxiety disorder. II. Comparative studies on sleep, awakening, daytime vigilance and anxiety under lorazepam plus diphen-hydramine (Somnium R) versus lorazepam alone, utilizing clinical, polysomnographic and EEG mapping methods. Neuropsychobiology 36: 130–152PubMedGoogle Scholar
  12. [12]
    Saletu-Zyhlarz G, Saletu B, Anderer P, Brandstätter N, Frey R, Gruber G, Klösch G, Mandl M, Grünberger J, Linzmayer L (1997) Nonorganic insomnia in generalized anxiety disorder. I. Controlled studies on sleep, awakening and daytime vigilance utilizing polysomnography and EEG mapping. Neuropsychobiology 36: 117–129Google Scholar
  13. [13]
    Grünberger et al (1999)Google Scholar

Copyright information

© Springer-Verlag Wien 2003

Authors and Affiliations

  • Josef Grünberger
    • 1
  1. 1.Universitätsklinik für PsychiatrieWienÖsterreich

Personalised recommendations